The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Acorda Therapeutics, Inc. on June 12, 2024. The debtor has been authorized to sell substantially all its assets to Merz Pharmaceuticals, LLC for a purchase price of $185 million in cash plus the amount, if any, of the Net Working Capital Adjustment.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2575 USD | +3.00% |
|
+0.98% | -98.29% |
06-12 | Motion for Asset Sale Approved for Acorda Therapeutics, Inc. | CI |
05-14 | Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-98.29% | 320K | |
+16.13% | 122B | |
+19.65% | 113B | |
+19.53% | 26.49B | |
-23.84% | 19.4B | |
-17.96% | 16.24B | |
-45.95% | 15.15B | |
-19.28% | 15.4B | |
+63.81% | 14.93B | |
+1.94% | 13.52B |
- Stock Market
- Equities
- ACOR.Q Stock
- News Acorda Therapeutics, Inc.
- Motion for Asset Sale Approved for Acorda Therapeutics, Inc.